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Abstract 
Malaria is an important cause of death and illness in children and adults, especially in tropical countries. The 
emerging resistance to ACTs by p. falciparum malaria threatens the health of the hundreds of millions of people 
routinely exposed to the risk of infection with this organism. One-arm prospective evaluation of clinical and 
parasitological responses of directly observed Artemether-Lumefantrine (Coartem®) treatment of uncomplicated 
Plasmodium falciparum malaria as per WHO  protocol 2009  was conducted  at Baddessa Health Center in 
Wolaita Zone, Southern Ethiopia from Feb to March, 2015. A total of 88 study participants were enrolled and 
followed for 42 days and 86 participants were completed follow up. There was 100%% an adequate clinical and 
parasitological response among participants who completed 42 days of follow-up. Two participants were 
excluded from study: one participant at day 7 due to self withdrawal and one participant at day 28 due to loss to 
follow up. However, relatively high proportion of patients (5.7%) still positive on day 3 in this study would 
indicate possible threat of artemisinin resistance development in the area and regular surveillance should to be 
continued as WHO recommendation. 
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Background 
Malaria is an important cause of death and illness in children and adults, especially in tropical countries (WHO 
2010). The burden of malaria is not limited only in life losses, but it also runs in money costs and resource 
expenditures. It is estimated that African countries spend more than 12 billion USD every year in direct losses 
for malaria control and averagely it retards the economic growth of the continent by 1.3% per year (WHO 2005). 
Up to 40% of African health budgets are spent on malaria aspects each year and averagely malaria suffering 
family loses a quarter of its income through treating and preventing the disease. Likewise, East African 
households spend significant sums (US$ 0.39 to 3.84/capita) per year in Sub-Saharan Africa to prevent and treat 
malaria (Joel G 2004).  
In Ethiopia malaria is still wide spread. Approximately 75% of Ethiopia‘s landmass is malaria-endemic; 
areas of disease are primarily associated with altitude and rainfall (Jima D 2010). In 2009/2010, malaria was the 
leading cause of outpatient visits and health facility admissions, accounting for 14% of outpatient visits and 9% 
of admissions (FMOH 2011). In 2010 about 4,068,764 clinical and confirmed malaria cases were reported as 
recorded in the 2011 World Malaria Report (WHO 2011). The estimated annual number of malaria-related 
illnesses, however, may range even higher (7 to 8 million per year), considering there is only 40% reporting 
completeness by Public Health Emergency Management (PHEM). P. falciparum and P. vivax are the dominant 
species of the malaria parasite in Ethiopia, in respective order (MIS 2011). 
Currently, Coartem® a fixed dose combination (FDC) drug of Artemether and Lumefantrine is used for 
the treatment of uncomplicated malaria and found to be safe and effective against P.falciparum and mixed 
infections including P. falciparum. In addition, it is effective against drug sensitive and resistant P. falciparum, 
and is recommended in areas where Plasmodium parasites are resistant to other antimalarial drugs (Payen et al. 
2005, Katzung et al. 2009). Ethiopia adopted Coartem® as the first line of drug for the treatment of 
uncomplicated P.falciparum malaria since 2004, after treatment failure reported to the previous anti malarial 
drugs (EFMOH 2004).  
Expanding access to artemisinin-based combination therapies (ACTs) in malaria-endemic countries has 
been integral to the remarkable recent success in reducing the global malaria burden. However, emerging 
resistance to ACTs by p. falciparum malaria threatens the health of the hundreds of millions of people routinely 
exposed to the risk of infection with this organism. More recently, there are reports in which p. falciparum is 
endemic. This is among major public health problem, which hinders the control of malaria (WHO 2010). 
In Ethiopia Artemether-Lumefantrine (Coartem®) efficacy was conducted at the national level in 2004 
during the replacement of previous P.falciparum anti-malaria drugs and recorded as 100% including Bahir Dar 
town (Kefyalew T et al. 2009). But, recent reports show the emergence of Coartem® resistance P.falciparum 
parasite (Eshetu et al 2012, Kinfu et al 2012). However, few studies were conducted relating to Artemether-
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Lumefantrine (Coartem®) efficacy and safety since national efficacy survey. Despite of wolaita being among 
malarious area there is no a single therapeutic efficacy study. So this study basically designed to assesses the 
current clinical and parasitological efficacy of six-dose regimen of Coartem® to fill this critical gap in the study 
area. 
 
Methods and materials 
Study setting and period 
One-arm prospective evaluation of clinical and parasitological responses of directly observed Artemether-
Lumefantrine (Coartem®) treatment of uncomplicated Plasmodium falciparum malaria as per WHO  protocol 
2009  was conducted  at Baddessa Health Center in Wolaita Zone, Southern Ethiopia from Feb to March, 2015. 
Wolaita is a Zone found in 329km south of Addis Ababa in Southern Nations, Nationalities and Peoples Region 
(SNNPR). Wolaita Zone is bordered on the south by Gamo Gofa, on the west by the Omo River which separates 
it from Dawro, on the northwest by Kembata Tembaro, on the north by Hadiya, on the northeast by the Oromia 
Region, on the east by the Bilate River which separates it from Sidama, and on the south east by the Lake Abaya 
which separates it from Oromia Region. The administrative center of Wolayita is Sodo. Based on 2007 
Population and housing census 2007 conducted by Central Statistical Authority of Ethiopia the zone has total 
population of above 1.5 million (Census 2007). 
Population 
Patients with the diagnosis of confirmed p.falciparum malaria at the study health facility in Wolaita Zone during 
the study period who has P. falcifarum mono-infection, asexual parasite count > 1000/µl; axillary temperature ≥ 
37.5 °C or presence of history of fever during the 48 h before recruitment; ability to swallow oral medication; 
ability and willingness to comply with the protocol for the duration of the study and to comply with the study 
visit schedule; absence of a clinical condition due to P. falcifarum malaria requiring hospitalization; absence of 
severe malnutrition according to WHO child growth standards (WHO, 2006); absence of a febrile condition due 
to diseases other than malaria; absence of regular medication, which might interfere with antimalarial 
pharmacokinetics; and perceived negative pregnancy or not breastfeeding were included in the study. 
Sample size determination 
The sample size was calculated using formula for single proportion in the population assuming a maximum of 
5% treatment failure in the population, at a confidence level of 95% and a precision of 5%. With a 20% increase 
to allow loss to follow-up and withdrawals during the 42 day follow-up period, a total of 88 study participants 
were enrolled. 
Patient recruitment and follow-up evaluation 
Treatment 
 People with uncomplicated p.falciparum malaria who met the study inclusion criteria was enrolled, treated with 
six doses Coartem® (Artemether 20mg + Lumefantrine 120mg in a fixed dose combination tablet) as per WHO 
2010 malaria treatment guideline based on age and body weight. Each dose of drug was administered under 
direct supervision at site and the study patients were observed for 30 minutes after medicine administration for 
vomiting. Any patient who vomits during this observation period was re-treated with the same dose of medicine 
and observed for an additional 30 minutes.  
Follow-up 
The follow-up will consist of a fixed schedule of check-up visits on days 0, 2, 3, 7, 14; 28 and 42 and 
corresponding clinical and parasitological examinations. Physical examination was being performed at the 
baseline (day 0 before dosing) and on days 2, 3, 7, 14, 28 and 42. A demographic information and contact details, 
complete medical history including malaria signs and symptoms and medication history were being screened at 
baseline in outpatient department and medical and medication history had been continuously assessed on each 
patient visit. 
Parasitological Investigation 
Finger-prick blood samples were collected from consenting patients for microscopic glass slides for thick and 
thin blood film preparation. Thick and thin blood films were prepared and stained with 10% Giemsa stain for 
parasite counts and was examined for screening on day 0 to confirm adherence to the inclusion criteria. Thick 
blood films were also examined on days 2, 3, 7, 14, 28, 42 or on any other day if the patient returns 
spontaneously. Parasite count was based on the number of asexual parasites observed against 200 leukocytes. 
This number was then multiplied by 40, to find an approximate count per microlitre of blood.  
  Parasite density (per µl) =   Average number of parasite counted x (600-800) WBCs 
Average number of leukocytes counted 
Haematological assessment (haemoglobin/haematocrit)  
Finger-pick blood sample was used to measure heamoglobin level using hematocrit technique on the scheduled 
days 0, 14 and 28 as per WHO 2009 protocol. 
Efficacy and Safety Evaluation 
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Treatment outcomes were classified on the basis of an assessment of the parasitological and clinical outcome of 
antimalarial treatment according to the WHO 2009 protocol as early treatment failure, late clinical failure, late 
parasitological failure or an adequate clinical and parasitological response.  
The incidences of any adverse events were documented. All patients were asked routinely about previous 
symptoms and about symptoms that had emerged since the previous follow-up visit and recorded on the case 
report form.  
Quality Assurance  
The investigators had strictly followed that the study protocol was being adhered to and that all data were 
collected and recorded correctly on the case report form. Parasite count was done by two laboratory technician 
so that any discordance on parasitic load calculation was done by averaging the two closest counts. Ten percent 
of randomly sampled slides were cross checked by a skilled parasitologist from Wolaita Sodo University 
Medical School.  
Data Analysis 
Data collected from in vivo therapeutic efficacy test was double entered and analyzed using SPSS software 
(version 20.0). 
Ethical Considerations 
Approval by the institutional ethical review committee was obtained before the study. Patients were included in 
the study only when they or guardians in the case of children gave informed consent. All information on patients 
remained confidential and shared only by the study team. 
 
Results 
Patients who were febrile and/or had history of fever with in past 24 hours of diagnosis were sent from outpatient 
department (OPD) to laboratory and diagnosed for malaria. Within study period total of 215 malaria cases were 
identified. Among which 27 were p.vivax, 32 were mixed infection, and remaining 156 cases were p.falciparum. 
Among positive cases, total of 127 malarial cases were excluded from study due to 27 p.vivax, 32 were mixed 
infection and 68 p.falciparum mono infections were excluded because of administration of other medication, 
severe malaria, pregnancy and low parasite load. Finally 88 p. falciparum malarial cases fulfilled inclusion 
criteria and were enrolled. Among 88 enrolled 1 was with drown from study at day 7 and 1 was lost to follow up 
at day 28 and 86 were completed 42 days of follow up. Among 88 participants 88.6% were adults and 60.2% 
were male (table 1).  
At day of enrollment the average axillary temperature was 39.5ᵒC and mean hemoglobin level was 
10.79mg/dl (table 2). When baseline clinical parameters of study participants distributed to age and sex relatively 
higher parasite density was recorded by adults than pediatrics and higher parasite density in male than female 
(table3). However, we did not find statistically significant difference between age groups in t-test for equality of 
means (p = 0.81) and between sex in t-test for equality of means (p = 0.36). We found higher day 0 parasite load 
in patients with anemia (4484.65/ µl) than non-anemic (3211.76/ µl) group which was statistically significant by 
t-test for equality of means (p = 0.025).  There was no significant difference in hemoglobin concentration among 
age groups by t-test for equality of means (p = 0.508).  
Generally fever and parasite clearance rate look like collinear as shown on figure1. There was 59.1% 
fever clearance and 72.2% parasite clearance on day 2. On day 3 there was 93.2 % fever clearance and 94.3% 
parasite clearance. However, we did not detected any significant correlation between fever clearance time and 
parasite clearance time (Pearson correlation, r = 0.061, P = 0.57).  
There was no treatment failure among participants who completed 42 days of follow-up. Two 
participants were excluded from study: one participant at day 7 due to self withdrawal and one participant at day 
28 due to loss to follow up (Table 4).  
At day of enrollment 80.69% participants were anemic and it was decreased to 65.9% at the 28th day of 
follow up (Table 5). There is linear increment of hemoglobin level in both age groups. Safety profile of 
Artemether-Lumefantrine recorded during follow up period was presented on table 6 below. 
 
Discussion  
In this study, we carried out therapeutic efficacy study of artemether-lumefantrine (Coartem®) on uncomplicated 
P. falciparum for the first time in this study area since adopted as a first fine drug in Ethiopia in 2004. In general, 
this  study  revealed  that  the  efficacy  of  the  drug was  100% without  any  severe  adverse effects. The high 
cure rates noted in this study are consistent with the baseline assessment conducted in 2003 prior to the 
implementation of artemether-lumefantrine as  first line drug in Ethiopia (Jima D 2005), more recent studies in 
Ethiopia (Kefyalew T et al. 2009, Hwang et al. 2011) and studies in other African countries (Ogouyèmi‑Hounto 
et al. 2016, Abuaku et al.  2016). However, in other studies in Ethiopia there were failure reports (Kinfu et al. 
2012, Eshetu et al. 2012). This is true in other African studies that some area had failure reports and other area 
had 100% adequate clinical and parasitological response (Ogouyèmi‑Hounto et al. 2016).  
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Day three fever and parasite clearance rate in this study were 93.2 % and 94.3 respectively. This finding 
is relatively consistency with some studies conducted in Ethiopia and other parts of the Africa (Ebstie et al. 2015, 
Getnet et al.  2015). However, the rate of parasite clearance time is somewhat longer than older reports in 
Ethiopia (Kefyalew T et al 2009, Kinfu et al. 2012). The emerging resistance to artemisinins can be 
characterized by slow parasite clearance in vivo and increased day 3 positive cases (Dondorp AM et al.  2009,  
Noedl H et al. 2008, Stepniewska K et al. 2010). In this regard the observed higher parasite clearance time may 
necessitate regular monitoring therapeutic efficacy according to WHO recommendation (WHO 2009). 
Parasite clearance time is not associated with both age and sex of participant (OR= 1.140, CI (0.434, 
2.994), p-value=0.79) and (OR= 1.160 CI (.297, 25.930), p-value=0.84) respectively. Binary logistic analysis 
showed that the only base line characteristic that affected parasite clearance time was parasite density at day 0. 
The parasite clearance time was significantly associated with baseline parasite load (p= 0.013). This was because 
of the higher density of the parasite at day 0 which prolongs the parasite clearance time. Geometric mean 
parasite at day 0 for all participant was 4238/ µl where as geometric mean parasite density among participants for 
those parasitemia cleared after day 2 was 5189 which was significantly higher (p=0.009). This result is similar 
with studies in Ethiopia (Kinfu et al. 2012) Sudan (Salah 2006). Even though, parasite clearance is look like 
collinear with fever clearance statistically there was insignificant correlation (Pearson correlation, r = 0.061, P = 
0.57). This is consistent with a study was conducted in Northern Ethiopia (Ebstie et al. 2015).  
Baseline parasite density was significantly higher in anemic individuals than non-anemic individuals (p 
= 0.025).  Anemic cases decreased from 80.7 % at baseline to 65.9% at day 28. Even though at day 7 parasite 
clearance was 100%, the anemic cases decreased by only 14.8% at day 28. This may be due to anemia may have 
risk factors like nutrition or intestinal helminthes which is common in the area (Bereket and Zewdneh 2015, 
Assefa 2010).  
The observed adverse effects of AL in the study were similar between adults and children and 
commonly reported by also other studies and are mild to moderate (Ebstie et al. 2015, Kefyalew T et al 2009). 
The most common adverse events were headache, abdominal pain, and loss of appetite.  
 
Conclusion  
Artemether-lumefantrine remains a effective and well tolerated drug for the treatment of uncomplicated 
falciparum malaria in the study area. However, relatively high proportion of patients still positive on day 3 in 
this study would indicate possible threat of artemisinin resistance development in the area and regular 
surveillance should to be continued as WHO recommendation. 
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Tables and Figures 
Table 1. Age and sex of the study participants on the day of enrollement, in Wolaita Zone, Feb to March, 2015. 
Demographic Characteristics Value at day of admission (Day 0) 
Age groups (years) 
 
5–14 10(11.4%) 
˃14 78(88.6%) 
Sex 
 
Male 53(60.2%) 
Female 35(39.8%) 
 
Table 2. Baseline clinical parameters of study participants in Wolaita Zone, Feb to March, 2015. 
Clinical parameters Mean ± SD  Range (Min. Max) 
Axillary temperature in degree celicious  39.549 ±1.3265 37.0 42.0 
Asexual parasite count  4238.75 ± 2109.498 1297 11000 
Hemoglobin level 10.79 ± 1.6157 7.0 14.0 
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Table 3. Base line clinical characteristics of participants stratified by age and sex in Wolaita Zone, Feb to March, 
2015. 
Demographic  Mean body Temp.(°C) Geometric mean parasite/µl Mean Hemoglobin level 
Age group 5–14 39.27 4088.3 10.47 
˃14 39.58 4258.04 10.83 
Sex  Male 39.43 4406.42 10.56 
Female 39.73 3984.86 11.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Treatment outcome of study participants versus days of follow up, in Wolaita Zone, Feb to March, 2015. 
Follow-up 
days 
PR W ACPR % Treatment Failures TTF 
ETF LCF LPF 
0 88 0 - - - - - 
2 88 0 100 0 0 0 0 
3 88 0 100 0 0 0 0 
7 87 1 100 0 0 0 0 
14 87 0 100 0 0 0 0 
28 86 1 100 0 0 0 0 
42 86 0 100 0 0 0 0 
PR=Population at risk, W=Excluded from the study (1 withdrawal and 1 loss to follow up), ACPR = Adequate 
clinical and parasitological response, ETF = Early treatment failure, LCF = late clinical failure, LPF = late 
parasitological failure, TTF= Total Treatment failure. 
 
Table 5. Summary of average hemoglobin level stratified by age in Wolaita Zone, Feb to March, 2015. 
Age group by years Mean Hemoglobin level by g/dl 
Day 0 Day 14 Day 28 
5–14 10.47 11.65 12.18 
˃14 10.83 11.96 12.45 
Total mean 10.8 11.9 12.4 
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Fig.1. Summary of Parasite load and fever clearance trends during 42 days of follow-up in Wolaita 
Zone, Feb to March, 2015. 
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Table 6. Adverse effects of drug reported during study period stratified by age group in Wolaita Zone, Feb to 
March, 2015. 
Adverse effect Age group in years  Total (89) 
5–14 (10) ˃14 (78%)  
Headache  2 (20%) 15(19.2%) 17(19.3%) 
Abdominal pain 2 (20%) 12(15.4%) 16(18.18%) 
Loss of appetite 3 (30) 10(12.8%) 13(14.77%) 
Weakness  2 (20%) 5(6.4%) 7(7.9%) 
Dizziness  0 6(7.7%) 6(6.8%) 
Sore throat 1(10%) 2 (2.5%) 3(3.4%) 
Joint pain 0  3(3.8%) 3(3.4%) 
 
